Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Mar 20;29(5):865-79.
doi: 10.1089/neu.2011.2052. Epub 2012 Feb 29.

A systematic review of the effects of pharmacological agents on walking function in people with spinal cord injury

Affiliations

A systematic review of the effects of pharmacological agents on walking function in people with spinal cord injury

Antoinette Domingo et al. J Neurotrauma. .

Abstract

Studies of spinalized animals indicate that some pharmacological agents may act on receptors in the spinal cord, helping to produce coordinated locomotor movement. Other drugs may help to ameliorate the neuropathological changes resulting from spinal cord injury (SCI), such as spasticity or demyelination, to improve walking. The purpose of this study was to systematically review the effects of pharmacological agents on gait in people with SCI. A keyword literature search of articles that evaluated the effects of drugs on walking after SCI was performed using the databases MEDLINE/PubMed, CINAHL, EMBASE, PsycINFO, and hand searching. Two reviewers independently evaluated each study, using the Physiotherapy Evidence Database (PEDro) tool for randomized clinical trials (RCTs), and the modified Downs & Black scale for all other studies. Results were tabulated and levels of evidence were assigned. Eleven studies met the inclusion criteria. One RCT provided Level 1 evidence that GM-1 ganglioside in combination with physical therapy improved motor scores, walking velocity, and distance better than placebo and physical therapy in persons with incomplete SCI. Multiple studies (levels of evidence 1-5) showed that clonidine and cyproheptadine may improve locomotor function and walking speed in severely impaired individuals with incomplete SCI. Gains in walking speed associated with GM-1, cyproheptadine, and clonidine are low compared to those seen with locomotor training. There was also Level 1 evidence that 4-aminopyridine and L-dopa were no better than placebo in helping to improve gait. Two Level 5 studies showed that baclofen had little to no effect on improving walking in persons with incomplete SCI. There is limited evidence that pharmacological agents tested so far would facilitate the recovery of walking after SCI. More studies are needed to better understand the effects of drugs combined with gait training on walking outcomes in people with SCI.

PubMed Disclaimer

Conflict of interest statement

Author Disclosure Statement

No competing financial interests exist.

Figures

Figure 1
Figure 1

Similar articles

Cited by

References

    1. Adams M, Hicks A. Spasticity after spinal cord injury. Spinal Cord. 2005;43:577–586. - PubMed
    1. AHFS Drug Information. American Society of Health-System Pharmacists, Inc; 2011.
    1. Anden NE, Haeggendal J, Magnusson T, Rosengren E. The time course of the disappearance of noradrenaline and 5-Hydroxytryptamine in the spinal cord after transection. Acta Physiol Scand. 1964;62:115–118. - PubMed
    1. Anden NE, Jukes MG, Lundberg A. The effect of DOPA on the spinal cord 2. A pharmacological analysis. Acta Physiol Scand. 1966;67:387–397. - PubMed
    1. Anderson KD. Targeting recovery: priorities of the spinal cord-injured population. J Neurotrauma. 2004;21:1371–1383. - PubMed

Publication types

MeSH terms